Mouse anti-Human CD25 Monoclonal Antibody | anti-CD25 antibody

CD25 (Tac antigen, p55, Interleukin 2 Receptor alpha, IL2Ra, T Cell Growth Factor Receptor) (MaxLight 490)

Cat. Num. AAA6253506

• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay, Immunoprecipitation
• Purity: Purified by Protein A Affinity Chromatography.
• Synonyms: CD25; Monoclonal Antibody; CD25 (Tac antigen; p55; Interleukin 2 Receptor alpha; IL2Ra; T Cell Growth Factor Receptor) (MaxLight 490); anti-CD25 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1
• Clone Number: 3H1147
• Specificity: Recognizes the ~55kD alpha subunit of the human CD25.
• Purity/Purification: Purified by Protein A Affinity Chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. Labeled with MaxLight490.

• Applicable Applications for anti-CD25 antibody: Flow Cytometry (FC/FACS), Immunoprecipitation (IP)
• Immunogen: Human PHA blasts; day 3 of culture.
• Conjugate: MaxLight490
• Preparation and Storage: Store at 4 degree C. Do Not Freeze.

Testing Data

(Figure A. Alexa®647 conjugated mouse anti human CD4 and RPE conjugated Mouse IgG1 isotype control MBS655766. Figure B. Alexa®647 conjugated mouse anti human CD4 and RPE conjugated mouse anti human CD25 (I7663-31P3). All experiments performed on red cell lysed human peripheral blood gated on lymphocytes.)

Flow Cytometry (FC/FACS)

(Potency of Treg-suppression is dependent on strength of stimulus and on Effector: Treg cell (E:T) ratio. (A) Typical FACS plot displaying purity of effector (CD4+CD25-) and Treg (CD4+CD25+) populations in healthy control subjects. (B) Mean counts per minute (CPM) (+SEM) uptake of tritiated thymidine in CD25- effector T cells from healthy controls (N = 27) stimulated with mitogenic CD3/28 beads at 2:1 and 0.2:1 bead: cell ratios. (C) Mean CPM (+SEM) in CD25- effectors v CD25+ Treg cells stimulated with mitogenic CD3/28 beads at 2:1 bead: cell ratio. (D) Mean (+SEM) percentage suppression of effector cell)

Testing Data

(Detection of circulating CD4+CD25low/-GITR+cells in SLE patients.(A) Flow-cytometry analysis of anti-GITR and anti-CD25-stained CD4+ T lymphocytes, freshly isolated from blood of a representative SLE patient, reveals the presence of a CD25-GITR+ cell subpopulation. Left panel: gating strategy. Gated CD4+ T lymphocytes were stained with isotype control Abs (middle panel) or anti-GITR and anti-CD25 Abs (right panel). (B) the levels of CD25 expression were evaluated in the upper left and lower left quadrants and MFI is reported. (C) mRNA expression of CD25 (FAM6 fluorochrome) in the indicated)

Product Categories/Family for anti-CD25 antibody

Antibodies; CD Markers

References

1. Prager, E., et al., Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor: ligand pathway in T cells, J. Immunol. 166: 2364-2371 (2001). 2. Thorborn, G. et al. (2010) Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection. PLoS One. 5: e9254. 3. Cutler, A.J. et al. (2010) Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol. 185: 6617-23. 4. Lawson, J.M. et al. (2008) Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol. 154: 353-9. 5. Holderness, J. et al. (2007) Select plant tannins induce IL-2Ralpha up-regulation and augment cell division in gammadelta T cells. J Immunol. 179: 6468-78. 6. Zhang, Y. et al. (2013) Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism. PLoS Pathog. 9 (4): e1003310. 7. Nocentini, G. et al. (2014) Expansion of regulatory GITR + CD25 Low/- CD4 + T cells in systemic lupus erythematosus patients. Arthritis Res Ther. 16: 444. 8. Soukup, K. et al. (2015) The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis. J Immunol. 195 (2): 541-52. 9. Kusunoki, Y. et al. (2010) T-cell immunosenescence and inflammatory response in atomic bomb survivors. Radiat Res. 174 (6): 870-6. 10. Bughani, U. et al. (2017) T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 12 (7): e0180088. 11. Knutson, K.L. et al. (2015) Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother. 64 (12): 1495-504.